ENDRA Life Sciences Inc. — fact timeline

ENDRA Life Sciences Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“April 20, 2026, the Staff issued a letter to the Company indicating that, because the Company’s stockholders’ equity as reported in its Annual Report on Form 10-K for the year ended December 31, 2025 was $2,260,120, the Company is no longer in compliance with Minimum Stockholders’ Equity Requirement. The Staff’s letter indicated that the Company’s non-compliance would result in the delisting of the Company’s securities from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company intends to timely request a hearing before the Panel, which”

ENDRA Life Sciences Inc. reported the quarter and year ended December 31, 2025 results: net income net loss of $3.2 million.

“in the fourth quarter of 2025 decreased to $1.6 million, compared with $4.3 million in the same period last year. As a result, the net loss in the fourth quarter of 2025 was $3.2 million, compared with a net loss of $4.2 million in the fourth quarter of 2024. 2025 Financial Results During 2025 the Company benefitted from actions taken throughout 2024 to”

ENDRA Life Sciences Inc. announced a restructuring with charges of approximately $51,000.

“on March 19, 2026, the Company reduced the number of its employees in order to reduce cash expenditures and extend its operational runway. As a result, the Company expects to incur pre-tax cash charges of approximately $51,000 associated with severance payments to former employees.”

ENDRA Life Sciences Inc.: Increased authorized common stock from 20,000,000 shares to 1,000,000,000 shares via Certificate of Amendment to Fourth Amended and Restated Certificate of Incorporation (effective 2025-12-10).

“At the Annual Meeting, the Company’s stockholders approved and adopted a Certificate of Amendment to the Company’s Fourth Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to increase the number of authorized shares of Company’s common stock, par value $0.0001 (the “Common Stock”), from 20,000,000 shares to 1,000,000,000 shares (the “Share Increase Amendment”). The Share Increase Amendment was filed with the Secretary of State of the State of Delaware on December 10, 2025 and was effective upon filing.”

Alexander Tokman was appointed as Acting Chief Executive Officer and Chairman at ENDRA Life Sciences Inc..

“Appointment of Alexander Tokman as Acting Chief Executive Officer Effective August 13, 2024, the Board appointed Alexander Tokman as the Company’s acting Chief Executive Officer and Chairman.”

Francois Michelon resigned as Chief Executive Officer and Director at ENDRA Life Sciences Inc..

“Francois Michelon Resignation On August 12, 2024, ENDRA Life Sciences Inc. (“ENDRA” or the “Company”) and Francois Michelon mutually agreed on Mr. Michelon’s resignation as the Company’s Chief Executive Officer and as a member of the Company’s Board of Directors (the “Board”), effective August 12, 2024.”

Richard Jacroux was appointed as Head of Finance at ENDRA Life Sciences Inc..

“On August 8, 2024, the Company’s Board of Directors (the “Board of Directors”) appointed Richard Jacroux as Head of Finance.”

Irina Pestrikova resigned as Senior Director, Finance at ENDRA Life Sciences Inc..

“On August 5, 2024, Irina Pestrikova notified ENDRA Life Sciences Inc. (“ENDRA” or the “Company”) of her resignation as the Company’s Senior Director, Finance, effective August 7, 2024.”

ENDRA Life Sciences Inc. reported the three months ended March 31, 2024 results: net income $2.8 million, or $0.26 per share, EPS $0.26 per share.

“Net loss in the first quarter of 2024 was $2.8 million, or $0.26 per share, compared with a net loss of $2.9 million, or $0.93 per share, in the first quarter of 2023.”

ENDRA Life Sciences Inc. reported the fiscal quarter ended March 31, 2024 results: net income We expect to record a net loss of approximately $2.8 million for the quarter ended March 31, 2024.

“On May 10, 2024, ENDRA Life Sciences Inc. (the “Company”) filed a Registration Statement (the “Prospectus”) on Form S-1/A (No. 333-278842) pursuant to the Securities Act of 1933, as amended (the “Securities Act”), relating to a public offering (the “Offering”) of shares of the Company’s common stock and warrants to purchase shares of the Company’s common stock. The Prospectus contains select preliminary unaudited estimated financial results for the fiscal quarter ended March 31, 2024.”

ENDRA Life Sciences Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“May 3, 2024, ENDRA Life Sciences Inc. (the “Company”) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company no longer meets the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”). The notification has no immediat”

ENDRA Life Sciences Inc. reported the year ended December 31, 2023 results: net income Net loss in 2023 was $10.1 million, or $1.58 per share, EPS $1.58 per share.

“Net loss in 2023 was $10.1 million, or $1.58 per share, compared with a net loss of $13.2 million, or $4.56 per share, in 2022.”

ENDRA Life Sciences Inc. reported the quarter and year ended December 31, 2023 results: net income Net loss in the fourth quarter of 2023 was $1.5 million, or $0.17 per share, EPS $0.17 per share.

“Net loss in the fourth quarter of 2023 was $1.5 million, or $0.17 per share, compared with a net loss of $3.3 million, or $1.04 per share, in the fourth quarter of 2022.”